Iovance Biotherapeutics, Inc. (IOVA) Buy Target $31.63 – Sell Target $36.42

Trade Setup

Buy Target $31.63
Sell Target $36.42

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells. The company’s lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer.